Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ibrexafungerp Citrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 93,700Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of October 18, 2023
    Enforcement Report - Week of October 18, 2023

    18 Oct 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-18-2023-24260.pdf

    FDA
    18 Oct 2023
    Share Share
    SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME
    SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME

    27 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/28/2750829/0/en/SCYNEXIS-Issues-a-Voluntary-Nationwide-Recall-of-BREXAFEMME-ibrexafungerp-tablets-due-to-potential-for-cross-contamination-with-a-non-antibacterial-%C3%9F-lactam-drug-substance.html

    GLOBENEWSWIRE
    27 Sep 2023
    Share Share
    SCYNEXIS and Hansoh Announce NMPA Acceptance of NDA for Ibrexafungerp
    SCYNEXIS and Hansoh Announce NMPA Acceptance of NDA for Ibrexafungerp

    20 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/20/2708345/0/en/SCYNEXIS-and-Hansoh-Pharma-Announce-NMPA-Acceptance-of-the-New-Drug-Application-for-Ibrexafungerp-in-China.html

    GLOBENEWSWIRE
    20 Jul 2023
    Share Share
    SCYNEXIS Achieves $25M GSK Development Milestone
    SCYNEXIS Achieves $25M GSK Development Milestone

    21 Jun 2023

    // CONTRACTPHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2023-06-21/scynexis-achieves-25m-gsk-development-milestone/

    CONTRACTPHARMA
    21 Jun 2023
    Share Share
    SCYNEXIS Reports Closing of Agreement with GSK for BREXAFEMME
    SCYNEXIS Reports Closing of Agreement with GSK for BREXAFEMME

    12 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/12/2667755/0/en/SCYNEXIS-Reports-Closing-of-Exclusive-License-Agreement-with-GSK-for-BREXAFEMME-Ibrexafungerp-Tablets.html

    GLOBENEWSWIRE
    12 May 2023
    Share Share
    Scynexis to Present Ibrexafungerp Data at the 33rd Annual ECCMID April 15-18
    Scynexis to Present Ibrexafungerp Data at the 33rd Annual ECCMID April 15-18

    13 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/13/2646187/0/en/SCYNEXIS-to-Present-Ibrexafungerp-Data-at-the-33rd-Annual-European-Congress-of-Clinical-Microbiology-Infectious-Diseases-ECCMID-April-15-18-in-Denmark.html

    GLOBENEWSWIRE
    13 Apr 2023
    Share Share